With the growing demand for virtual care and an increasingly mobile population, the need to improve communication with non-English-speaking patients is immense. 

A new study on the implications of AI shortcutting has experts raising concerns about the integration of the technology into medicine.

FDA Commissioner Robert Califf, MD, explains the need for hospitals to perform quality assurance checks on clinical artificial intelligence to ensure these technologies don't "drift" from what was originally cleared by the FDA.
 

Researchers hope their findings can help pave the way for more targeted therapies for individuals with Crohn's disease.

As these models continue to advance, it is important to understand how their performance holds up over time.